Melanoma

Why trials studying Melanoma stopped, in this sample of ClinicalTrials.gov.

38 stopped trials with a clear reason; 89% ended for non-scientific reasons.

Trials

• Exploratory Study of Inhaled Afatinib Dimaleate PK Profile
  NCT06897735 · TERMINATED · other
  “adjustment of the study design taking into account the receipt of primary data”
• Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy®
  NCT06587451 · TERMINATED · funding business
  “In light of the evolving regulatory landscape and growing indications that major Health Authorities will move towards a streamlined clinical development, Sandoz took a strategic decision and is winding down its CJPB898A12301 clinical study.”
• Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
  NCT06052852 · TERMINATED · funding business
  “Sponsor decision”
• Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors
  NCT05909995 · TERMINATED · funding business
  “This was a strategic business decision. There were no safety concerns contributing to this decision.”
• NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
  NCT05714553 · TERMINATED · funding business
  “The NuTide:303 study was terminated at NuCana's discretion following refinement of the NUC-3373 development strategy.”
• A Trial of Intratumoural Tigilanol Tiglate in Adult Participants With Stage IIIB to IV M1c Melanoma
  NCT05234437 · TERMINATED · slow accrual
  “Insufficient Patient Recruitment Rates”
• Immunogenicity and Safety of Pneumococcal Vaccination in Patients Treated With Immune Checkpoint Inhibitors
  NCT03989050 · WITHDRAWN · logistics pi
  “Administrative reasons”
• A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment
  NCT03978611 · TERMINATED · funding business
  “Business objectives have changed.”
• A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
  NCT04725331 · TERMINATED · funding business
  “Sponsor decision following completion of Phase I part not driven by safety reason”
• Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors
  NCT04116320 · TERMINATED · slow accrual
  “Unable to enroll enough patients to complete targeted enrollment in a reasonable time.”
• Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
  NCT04234113 · TERMINATED · futility
  “Due to lack of efficacy shown at the time of the interim analysis.”
• A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma
  NCT04337931 · TERMINATED · funding business
  “Business decision (not due to safety reason).”
• Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
  NCT04106167 · TERMINATED · funding business
  “This study was terminated by the Sponsor.”
• A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
  NCT03829501 · TERMINATED · funding business
  “Early discontinuation based on strategic sponsor decision not driven by any safety concerns.”
• Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer
  NCT03111901 · WITHDRAWN · funding business
  “funding was withdrawn”
• Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA)
  NCT03354962 · TERMINATED · slow accrual
  “Slow recruitment rate”
• PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
  NCT03685591 · TERMINATED · funding business
  “The decision to stop enrollment was due to strategic considerations and not due to any specific safety reasons or request from a regulatory authority.”
• Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists
  NCT03412058 · TERMINATED · slow accrual
  “The study was terminated prematurely due to insufficient patient recruitment”
• Vemurafenib Plus Cobimetinib in Advanced or Metastatic Melanoma Patients
  NCT03224208 · TERMINATED · slow accrual
  “low enrolment rate”
• REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies
  NCT03435640 · TERMINATED · funding business
  “Based on the overall results from the Phase 1 part of the study the sponsor decided to end the study. The decision was not due to safety reasons.”
• SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients
  NCT03126461 · WITHDRAWN · slow accrual
  “the project was never initiated and no participants were enrolled, it was closed permanently”
• Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma
  NCT02719015 · WITHDRAWN · regulatory
  “No IND Serial #”
• A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma
  NCT03207867 · TERMINATED · funding business
  “Sponsor decision”
• 18F-FLT PET Imaging in Patients With Advanced Melanoma
  NCT02891616 · TERMINATED · slow accrual
  “Low accrual rate”
• Yervoy Pregnancy Surveillance Study
  NCT02854488 · WITHDRAWN · slow accrual
  “During the study period, no participants were enrolled in the study despite extensive recruitment methods.”
• A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)
  NCT02576665 · TERMINATED · funding business
  “Sponsor decision”
• A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
  NCT02452424 · TERMINATED · futility
  “Terminated early for insufficient evidence of clinical efficacy”
• Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma
  NCT02425306 · TERMINATED · slow accrual
  “Slow accrual to part 2 of the study. Accrual to part 1 is complete.”
• Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients
  NCT02143050 · WITHDRAWN · slow accrual
  “No participant enrollment”
• A Pilot/Phase II Study of Gamma Knife Radiosurgery for Brain Metastases Using 3Tesla MRI and Rational Dose Selection
  NCT02005614 · TERMINATED · slow accrual
  “Unable to recruit patients.”
• Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
  NCT01495988 · TERMINATED · slow accrual
  “Slow accrual; toxicity; change in priorities”
• Safety and Efficacy of Intramuscular Electrotransfer of Plasmid AMEP in Patients Suffering From Advanced or Metastatic Melanoma
  NCT01764009 · WITHDRAWN · slow accrual
  “Study stopped due to low enrolment rate.”
• Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation
  NCT01474551 · TERMINATED · slow accrual
  “Lack of accrual”
• Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients
  NCT01308294 · TERMINATED · slow accrual
  “Low enrollment rate”
• Determining the Lymphokine Activated Killer (LAK) Cytotoxicity Present in Patients Undergoing Interleukin-2 Therapy
  NCT01068470 · TERMINATED · logistics pi
  “PI left the institution”
• Feasibility and Functionality of fPAM Imaging in Melanoma
  NCT00776945 · TERMINATED · funding business
  “no funding”
• Biochemotherapy With Temozolomide for Metastatic Melanoma
  NCT00505635 · TERMINATED · slow accrual
  “Slow accrual”
• Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma
  NCT00512798 · TERMINATED · futility
  “This study was terminated due to lack of efficacy”

Reasons are labeled automatically and are unverified. See the methodology. This is research information, not medical advice. Search the full database.